Overview
Cleveland Diagnostics develops novel blood-based diagnostic tests for early cancer detection, focusing on prostate cancer with its IsoPSA test to reduce unnecessary biopsies. The company's IsoClear platform analyzes protein structural differences for higher accuracy and specificity in identifying cancer biomarkers. They offer lab-friendly, affordable tests expanding to additional cancers, supported by partnerships like Quest Diagnostics.
Frequently asked questions
- What is IsoPSA and its primary use?
- IsoPSA is a blood test that measures protein structural differences to detect prostate cancer risk and high-grade disease, helping rule out unnecessary biopsies with greater accuracy.
- What technology powers Cleveland Diagnostics' tests?
- The IsoClear platform and Solvent Interaction Analysis (SIA) technology analyze protein structures in blood to determine biomarker origins from cancer cells, improving diagnostic specificity.
- What are the company's partnerships and capabilities?
- Cleveland Diagnostics partners with Quest Diagnostics for expanded IsoPSA access and has collaborations like Genomic Health; they operate a state-of-the-art facility for testing, R&D, and scalability in cancer diagnostics.